Marine protein is probably inevitable. Nobody has clinically validated it properly yet. SeaCrunch intends to be first.
Seaweed cultivation requires no land, no freshwater, no fertilisers. Environmental credentials that exceed even plant-based alternatives. Consumer demand, policy alignment, and supply infrastructure are converging.
Compositional analyses are extensive. But there is a near-total absence of gold-standard human clinical data measuring amino acid absorption or muscle protein synthesis. That void is the real commercial and regulatory barrier.
We are the commercialisation and research coordination platform. We commission independent evidence, convene the right partnerships, and build the technical infrastructure that the entire category will require. The science belongs to the researchers. The first-mover position belongs to SeaCrunch.
The scientific literature is unambiguous. Each problem has a defined solution. SeaCrunch's architecture is built to solve all four simultaneously. Companies that solve one or two fail.
Standard nitrogen analysis (Kjeldahl/Dumas) uses a 6.25 conversion factor. In seaweed, this is wrong. Non-protein nitrogen inflates all published figures. The correct factor is 4–5. Any claim built on conventional analysis is exposed to scientific challenge from day one.
Cell wall polysaccharides physically trap intracellular proteins. Without targeted processing, much of the protein content is biologically locked. Alkaline extraction yields ~7%; enzymatic combined methods yield ~11%. The IP sits in the extraction process, not the raw biomass.
No study has yet used stable isotope tracer methodology, the accepted gold standard for measuring muscle protein synthesis, in humans consuming seaweed protein. This evidentiary void is the primary regulatory, commercial, and investor barrier facing the entire category.
Protein yield from Palmaria palmata ranges 7–11% of dry weight. A single-product model competing with whey on unit economics is not viable. The solution is biorefinery: protein plus polysaccharides plus bioactives plus residual biomass, giving multiple revenue streams from one tonne.
"SeaCrunch is not a seaweed producer. It is a protein-unlocking technology company that uses seaweed as feedstock. The intellectual property sits in how the protein is extracted, not in what grows in the sea."
SeaCrunch is a food innovation company, not a research institution. This is deliberate. Research conducted independently, by world-class academic institutions with full publication rights and their own ethical governance, carries genuine scientific authority. That independence is not incidental to the evidence's commercial value. It is the source of it.
All findings will be published regardless of outcome. This commitment is unconditional. Negative results published honestly protect the scientific record and protect SeaCrunch from a far worse outcome: building a commercial programme on an ingredient that cannot perform as promised.
Randomised crossover design in physically active adults. Seaweed protein at two dose levels, a whey comparator, and a non-protein control. Blood amino acid profiles, gastrointestinal tolerance assessments, and dose-response characterisation. The foundation for everything that follows.
The most important question: does the processed ingredient actually absorb in human metabolism? Given protein rebinding risk and low PDCAAS scores in the literature, Phase One is the most critical binary risk in the business.
The definitive question: does seaweed protein stimulate muscle protein synthesis in humans at rates comparable to whey? Stable isotope tracers are the only approach accepted as definitive by regulatory authorities for health claim applications. Not a proxy; a direct measurement of the outcome of interest.
The primary output is a peer-reviewed manuscript in a leading nutrition or exercise science journal. This becomes the foundational citation for all subsequent commercial claims, health claim submissions, and regulatory applications. First-mover position in the scientific record; once taken, it cannot be claimed by others.
SeaCrunch is deliberately structured as a coordination platform. One of the most important aspects of the model is what it chooses not to do. The restraint increases credibility.
Internationally recognised for muscle protein metabolism research. Extensive published experience with stable isotope tracer methodology, the gold standard for measuring muscle protein synthesis. Independent protocol design, full publication rights, ethical governance entirely separate from SeaCrunch.
One of Europe's leading marine research institutes. World-class expertise in seaweed biology, UK species characterisation, cultivation systems, and marine biochemistry. Critical to SeaCrunch's species selection, biomass quality, and longer-term domestic supply chain development.
Part of the Orkla Group. Over £500 million UK revenue. Evidence-led product development, direct consumer relationships, manufacturing capability, and distribution networks. Their interest represents genuine commercial assessment. Customer base of health-conscious older adults alongside sports nutrition consumers aligns directly with marine protein's positioning.
Expertise spanning alternative protein commercialisation, algal extraction science, food functionality, flavour optimisation, and circular processing systems. Connectivity to UK innovation funding ecosystems, including Innovate UK and UKRI alternative protein programmes. A commercially oriented, translational research perspective.
We seek relationships with seaweed cultivators and processors working with red seaweed species in UK, Irish, Icelandic, or Norwegian waters. Validated demand transforms the economics of cultivation investment. Also: regulatory science expertise, food technology, and bioprocessing capability.
Marine protein is not only a nutrition story. It is a coastal economic development story, a climate story, a food security story, and a UK scientific leadership story, all simultaneously.
Seaweed cultivation requires nothing from terrestrial agriculture. No land displacement. No freshwater withdrawal. No fertilisers or pesticides. Active carbon sequestration during growth. If processing uses renewable energy, marine protein's net footprint can approach or exceed neutrality. No terrestrial protein source can make this claim.
The UK imports the vast majority of the seaweed it uses. The risk is not commodity seaweed; it is importing high-value, scientifically validated ingredients that the UK has every resource to develop domestically. Norway, Iceland, Ireland, and France are building capabilities. The window for UK leadership is open but not permanent.
The value chain, covering cultivation, processing, protein extraction, formulation, and distribution, creates employment across skill levels in coastal regions facing structural economic challenges following fishery decline. Scotland's Highlands and Islands, Wales, Cornwall, and Devon all possess the coastal resources and the economic need that seaweed sector development could address.
The first organisation to publish gold-standard human clinical evidence for seaweed protein's efficacy establishes a scientific record that others must cite, acknowledge, and build upon. Regulatory precedents set by UK-led research create standards that later applicants must meet. This position, once taken, cannot be retroactively claimed.
Every pound invested in Phase One and Phase Two reduces the probability of the most expensive outcome available to this business: building a commercial programme on an ingredient that cannot deliver what it promises.
The right to be the first published human clinical evidence in a category where that position cannot be retroactively claimed once taken. A citation record that every subsequent market entrant must acknowledge.
Proprietary enzymatic extraction protocols, optimised for Palmaria palmata, that translate directly into ingredient performance and competitive defensibility. Species-specific optimisation that cannot be purchased from existing literature.
Novel food dossier data generated through Phase One and Two, reducing the time and cost of market authorisation for SeaCrunch and creating precedents that benefit the company's position relative to later entrants.
First-mover brands in validated new categories command valuations and exit multiples that market followers cannot access. Marine protein is an unproven category today. SeaCrunch's role is to make it real.
For comparison: developing and launching a conventional food product typically absorbs £500,000–£2,000,000 before manufacturing and marketing costs. This is the most efficient capital deployment available at this stage.
Research · Investment · Industry · Supply Chain
Phase One raise open now. SEIS/EIS eligible. Phased structure.
Academic institutions with relevant expertise across the value chain.
Nutrition brands, ingredient manufacturers, commercial partners.
Seaweed cultivators and processors, particularly red species.
Press, policy engagement, and general enquiries.
